3 Branded Generics Maker, Contract Development Organisation and Apparel Exporter Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Anthem Biosciences and Pearl Global Industries
- November 4, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Emcure Pharmaceuticals, Anthem Biosciences and Pearl Global Industries: ROE of 18.7% to 19.4% and FY22 to FY26 revenue CAGR of 12.1% to 16.5%. Prices as of 3 Nov 2026.
Quick Answer
The three branded generic, CDMO and apparel export stocks to watch are Emcure Pharmaceuticals, Anthem Biosciences and Pearl Global Industries. Their return on equity ranges from 18.7% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.1% to 16.5%. Anthem Biosciences has the highest return on equity at 19.4%, while Pearl Global Industries has the fastest revenue growth at 16.5% a year. Prices are based on the 3 November 2026 close, and this article is educational, not investment advice.
Branded generic, CDMO and apparel export stocks offer a focused view of a sector where demand keeps widening. Emcure Pharmaceuticals, Anthem Biosciences and Pearl Global Industries cover a branded generics maker, a contract development organisation and an apparel exporter.
This list covers three branded generic, CDMO and apparel export stocks with complete current figures: Emcure Pharmaceuticals, Anthem Biosciences and Pearl Global Industries. Every figure comes from the latest reported financials and the 3 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Branded Generic, CDMO and Apparel Export Stocks?
Branded generic, CDMO and apparel export stocks are listed companies that sell branded generics in India and abroad, offer discovery, development and manufacturing services to global pharma firms, and make garments for international brands from factories in several countries. Their earnings depend on drug demand, outsourcing orders and apparel export orders.
Branded Generic, CDMO and Apparel Export Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals | 1,976.6 | 33,487 | 32.9 | 36.0 | 18.7 | 0.31 |
| Anthem Biosciences | 854.45 | 45,546 | 79.1 | 36.0 | 19.4 | 0.02 |
| Pearl Global Industries | 1,267.1 | 11,806 | 38.9 | 35.2 | 19.0 | 0.65 |
On valuation, Emcure Pharmaceuticals trades at a P/E below the industry P/E, while Anthem Biosciences and Pearl Global Industries trade above it, which reflects the growth the market already expects. Readers comparing branded generic, CDMO and apparel export stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in branded generic, CDMO and apparel export stocks can use the coming numbers to test whether growth is holding.
Why Do Branded Generic, CDMO and Apparel Export Stocks Have a Strong Roadmap in India?
Branded generic, CDMO and apparel export stocks have a strong roadmap in India because growing demand for medicines, rising pharma outsourcing and steady export orders for garments keep widening the market for these export linked companies.
- Branded generics. Marketing arms reach doctors across regions.
- Contract services. Global firms outsource development and manufacturing.
- Garment exports. International brands source from varied factories.
Why Emcure Pharmaceuticals Features Among These Branded Generic, CDMO and Apparel Export Stocks
Among the branded generic, CDMO and apparel export stocks on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.
The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0.
Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore.
Roadmap: It is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
What to watch: Look at the growth of the India branded business and the pace of new launches abroad.
Why Anthem Biosciences Features Among These Branded Generic, CDMO and Apparel Export Stocks
Among the pharma services and garment shares on this list, Anthem Biosciences is a research-driven contract development and manufacturing organisation that serves global pharma and biotech customers with discovery, development and manufacturing services.
Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%.
The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0.
Roadmap: The company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.
What to watch: Monitor the order pipeline from global customers and the ramp-up of newer manufacturing capacity.
Why Pearl Global Industries Features Among These Branded Generic, CDMO and Apparel Export Stocks
Among the three companies on this list, Pearl Global Industries is a Gurugram-based apparel manufacturer and exporter that makes garments for leading international brands from factories in India, Bangladesh, Vietnam and Indonesia.
In the June 2026 quarter, revenue grew 24.2% year on year to Rs 1,539 crore, while net profit rose 51.4% to Rs 99.2 crore. Revenue rose from Rs 2,747 crore in FY22 to Rs 5,062 crore in FY26, a compound annual growth rate of 16.5%.
Net profit grew from Rs 70.1 crore in FY22 to Rs 270 crore in FY26, which works out to a compound annual growth rate of 40.1%. The company has a return on equity of 19.0%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 11,806 crore. The stock trades at a P/E of 38.9, above the industry P/E of 35.2.
Roadmap: The company benefits from global brands diversifying their sourcing away from a single country, and its multi-country footprint helps it serve them. Capacity additions and a growing retail brand portfolio add to its growth levers.
What to watch: Watch order inflow from global brands and the ramp-up of newer factories.
Emcure Pharmaceuticals vs Anthem Biosciences vs Pearl Global Industries on Key Financials
The table below sets the three branded generic, CDMO and apparel export stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Emcure Pharmaceuticals | 5,919 | 9,335 | 12.1% | 941 | 10.1% |
| Anthem Biosciences | 1,280 | 2,280 | 15.5% | 592 | 26.0% |
| Pearl Global Industries | 2,747 | 5,062 | 16.5% | 270 | 5.3% |
Anthem Biosciences posts the highest return on equity in this group at 19.4%. Emcure Pharmaceuticals has the largest FY26 revenue at Rs 9,335 crore, and Pearl Global Industries shows the fastest revenue growth with a 16.5% compound annual rate. A useful habit with branded generic, CDMO and apparel export stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Branded Generic, CDMO and Apparel Export Stocks
Every theme carries risks that deserve a check before any decision. For these branded generic, CDMO and apparel export stocks, the main points are: Long-term pharma services and garment shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Currency moves. Export earnings move with the rupee.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter branded generic, CDMO and apparel export stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Branded Generic, CDMO and Apparel Export Stocks
Branded generic, CDMO and apparel export stocks reward patient research into demand, execution and financial strength. Emcure Pharmaceuticals, Anthem Biosciences and Pearl Global Industries each have a clear plan to grow. Based on the 3 November 2026 close, Emcure Pharmaceuticals trades at Rs 1,976.6, Anthem Biosciences at Rs 854.45 and Pearl Global Industries at Rs 1,267.1. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these branded generic, CDMO and apparel export stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track branded generic, CDMO and apparel export stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are branded generic, CDMO and apparel export stocks?
Ans. Branded generic, CDMO and apparel export stocks are listed companies that sell branded generics in India and abroad, offer discovery, development and manufacturing services to global pharma firms, and make garments for international brands from factories in several countries. Their earnings depend on drug demand, outsourcing orders and apparel export orders. This list looks at three of them, Emcure Pharmaceuticals, Anthem Biosciences and Pearl Global Industries, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.
Which branded generic, CDMO and apparel export stocks are covered in this list?
Ans. This list covers Emcure Pharmaceuticals, Anthem Biosciences and Pearl Global Industries. Based on the 3 November 2026 close, Emcure Pharmaceuticals traded at Rs 1,976.6, Anthem Biosciences at Rs 854.45 and Pearl Global Industries at Rs 1,267.1. Their return on equity ranges from 18.7% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.1% to 16.5%.
Why do branded generic, CDMO and apparel export stocks have a strong future roadmap in India?
Ans. Branded generic, CDMO and apparel export stocks have a strong roadmap in India because growing demand for medicines, rising pharma outsourcing and steady export orders for garments keep widening the market for these export linked companies. The main drivers are as follows. Branded generics. Marketing arms reach doctors across regions. Contract services. Global firms outsource development and manufacturing. Garment exports. International brands source from varied factories. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Emcure Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
How has Anthem Biosciences performed financially?
Ans. Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0. Looking ahead, the company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.
How has Pearl Global Industries performed financially?
Ans. Revenue rose from Rs 2,747 crore in FY22 to Rs 5,062 crore in FY26, a compound annual growth rate of 16.5%. Net profit grew from Rs 70.1 crore in FY22 to Rs 270 crore in FY26, which works out to a compound annual growth rate of 40.1%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 1,539 crore, while net profit rose 51.4% to Rs 99.2 crore. The company has a return on equity of 19.0%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 11,806 crore. The stock trades at a P/E of 38.9, above the industry P/E of 35.2. Looking ahead, the company benefits from global brands diversifying their sourcing away from a single country, and its multi-country footprint helps it serve them. Capacity additions and a growing retail brand portfolio add to its growth levers.
What risks should investors check before buying branded generic, CDMO and apparel export stocks?
Ans. Investors should check a few risks before buying branded generic, CDMO and apparel export stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of branded generic, CDMO and apparel export stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
